The Food and Drug Administration has approved Promega’s OncoMate MSI Dx Analysis System as a companion diagnostic for identifying patients with microsatellite instability-high, or MSI-high, solid tumors who may be candidates for treatment with the immunotherapy Keytruda, according to OncLive.
The PCR-based test was developed in collaboration with Merck, the manufacturer of Keytruda. It measures MSI status in tumor tissue, a genetic characteristic that can help predict response to immune checkpoint inhibitors. The assay has also received FDA clearance to support identification of colorectal cancer patients who may need additional evaluation for Lynch syndrome, an inherited disorder that increases cancer risk.
For patients with advanced cancer that no longer responds to standard therapies, an MSI test can help clarify whether immunotherapy is appropriate. Because MSI-high tumors are relatively uncommon in many cancer types, patients may not always know whether this marker has been assessed.
Approval Details and the Test’s Regulatory History
The OncoMate system uses a fluorescent, multiplex PCR method to measure DNA fragment lengths and detect instability in microsatellites—short, repeated sequences of genetic code. Its approved companion diagnostic indications are listed in the FDA’s premarket approval records.
The test’s first FDA approval as a companion diagnostic came in November 2025, when it was cleared to identify patients with microsatellite-stable endometrial cancer who may benefit from Keytruda in combination with Lenvima. That designation marked Promega’s first FDA-approved companion diagnostic and followed the company’s collaboration with Merck. The latest approval expands its role to MSI-high solid tumors across cancer types.
“Our test connects patients with the therapy most likely to help them,” said Alok Sharma, Promega’s global clinical market director.
The announcements reviewed did not include new performance data, identify a supporting clinical trial, or provide independent expert commentary on the approval.
MSI-High Tumors and Keytruda’s Evidence Base
Normal cells repair small DNA copying errors through mismatch repair. When that system fails, errors accumulate in microsatellites, producing an MSI-high or mismatch repair-deficient tumor. These tumors often contain many abnormal proteins, which may make them more recognizable to the immune system after a checkpoint inhibitor releases its inhibitory signals.
Keytruda, known generically as pembrolizumab, became the first FDA-approved cancer therapy authorized on the basis of a tumor biomarker rather than the organ in which the cancer originated. Its accelerated approval in May 2017 was based on a 39.6% response rate among 149 patients, and it was converted to full approval in March 2023.
In pooled data from 504 patients with more than 30 tumor types, tumors shrank in 33.3% of participants, and 10.3% had a complete response. Among responders, 77% had responses lasting at least one year and 39% at least three years, with a median response duration of 63.2 months. These findings came from three nonrandomized phase 2 trials sponsored by Merck and were not compared directly with other treatments.
The indication covers adults and children with MSI-high or mismatch repair-deficient solid tumors that are unresectable or metastatic, have progressed after prior therapy, and lack satisfactory alternative options. Immune-related adverse events can be serious; among patients receiving Keytruda alone across studies, lung inflammation occurred in 3.4%, colitis in 1.7%, and hepatitis in 0.7%.
Patients Most Likely to Be Affected
MSI-high status is most commonly seen in endometrial, colorectal, and stomach cancers, but it can occur in other tumor types as well. Patients with advanced solid tumors can ask their care teams whether their cancer has been tested for MSI or mismatch repair, which method was used, and whether the result came from an FDA-approved companion diagnostic.
Mismatch repair status may also be assessed with immunohistochemistry, a staining technique that detects absent repair proteins, or with broader genomic sequencing panels. A companion diagnostic designation indicates that a specific test has been validated for selecting patients for a particular drug.
MSI and mismatch repair results now inform treatment decisions beyond advanced disease. In October, for example, the FDA granted accelerated approval to single-agent Jemperli for certain stage 2 or stage 3 rectal cancers that are mismatch repair-deficient or MSI-high, an option that may allow some patients to avoid surgery, chemotherapy, and radiation.
An MSI-high result can also have implications for family members. Some MSI-high tumors are associated with Lynch syndrome, so patients may be offered genetic counseling and blood or saliva testing to determine whether the condition is inherited. Such a finding can prompt earlier screening for relatives.
Coverage and Practical Testing Questions
Insurance coverage for tumor testing varies by health plan and test type. Patients can ask their oncology team whether the test is covered, whether prior authorization is required, and whether tissue from an earlier biopsy can be retested rather than collecting a new sample. Patients tested years ago may also request the full pathology or genomic report, as many receive only a brief summary of the result.
Keytruda is typically administered intravenously every three or six weeks, or through a subcutaneous formulation called Keytruda Qlex, for up to two years in this treatment setting. Hospital financial counselors and manufacturer assistance programs may help patients manage high out-of-pocket costs.
New cough, shortness of breath, persistent diarrhea, yellowing of the skin, severe fatigue, or rash during treatment should be reported promptly to the care team, because immune-related side effects can emerge months after therapy begins. Patients should not start or stop cancer treatment based on a test result without consulting an oncologist. MedicalDaily will report on any additional performance data released by Promega or the FDA.
Key Questions Answered
What did the FDA approve? Promega’s OncoMate MSI Dx Analysis System as a companion diagnostic for identifying MSI-high solid tumor patients who may be candidates for Keytruda.
What does MSI-high mean? The tumor has lost its ability to repair certain DNA copying errors, which may make it more responsive to immunotherapy.
How well does Keytruda work in MSI-high tumors? In pooled data from 504 patients, tumors shrank in 33.3% of patients, and most responses lasted at least one year.
What is the test’s link to Lynch syndrome? It was previously cleared to help identify colorectal cancer patients who may benefit from additional testing for Lynch syndrome.
Who should ask about MSI testing? Patients with advanced solid tumors, especially endometrial, colorectal, or stomach cancers, may want to ask whether MSI testing has been performed.
Does an MSI-high result affect family members? It can. Some MSI-high tumors are linked to inherited Lynch syndrome, so genetic counseling may be offered to patients and relatives.
Also Read
- Metformin Shows Promise in Long COVID Management; Lp(a) Reduction Emerges as Key Cardiovascular Strategy
- Illicit cigarettes at Sydney “clean beauty” launch prompt health investigation
- Virginia Confirms First Measles-Linked Death of 2026 in Young Child
- Surgeons Reconstructed Two Infected Heart Valves Using the Patient’s Own Pericardium

